Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-10-04
2009-11-03
Mondesi, Robert B. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C435S007100
Reexamination Certificate
active
07611714
ABSTRACT:
Methods and compositions for inducing an immune response againstPseudomonas aeruginosaare provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and aPseudomonaspilin peptide comprising an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), wherein the chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses saidPseudomonaspilin peptide to epithelial cells of said subject. In other aspects, the invention provides nucleic acids encoding chimeric immunogens of the invention, kits comprising chimeric immunogens of the invention, cells expressing chimeric immunogens of the invention, and methods of using chimeric immunogens of the invention.
REFERENCES:
patent: 4892827 (1990-01-01), Pastan et al.
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5223604 (1993-06-01), Hodges et al.
patent: 5328984 (1994-07-01), Pastan et al.
patent: 5445818 (1995-08-01), Hodges et al.
patent: 5458878 (1995-10-01), Pastan et al.
patent: 5468484 (1995-11-01), Hodges et al.
patent: 5494672 (1996-02-01), Hodges et al.
patent: 5512658 (1996-04-01), Pastan et al.
patent: 5573916 (1996-11-01), Cheronis et al.
patent: 5602095 (1997-02-01), Pastan et al.
patent: 5612036 (1997-03-01), Hodges et al.
patent: 5696237 (1997-12-01), Fitzgerald et al.
patent: 5705156 (1998-01-01), Pastan et al.
patent: 5705163 (1998-01-01), Pastan et al.
patent: 5854044 (1998-12-01), Pastan et al.
patent: 5863745 (1999-01-01), Fitzgerald et al.
patent: 5965406 (1999-10-01), Murphy
patent: 5980895 (1999-11-01), Pastan et al.
patent: 6011002 (2000-01-01), Pastan et al.
patent: 6022950 (2000-02-01), Murphy
patent: 6074644 (2000-06-01), Pastan et al.
patent: 6086900 (2000-07-01), Draper
patent: 6423513 (2002-07-01), Fitzgerald et al.
patent: 6426075 (2002-07-01), Fitzgerald et al.
patent: 6498233 (2002-12-01), Weis et al.
patent: 7314632 (2008-01-01), Fitzgerald
patent: 2002/0106370 (2002-08-01), Cardy et al.
patent: 2003/0054012 (2003-03-01), Fitzgerald et al.
patent: 2004/0071731 (2004-04-01), Fitzgerald
patent: 2005/0079171 (2005-04-01), Fitzgerald et al.
patent: 2006/0153798 (2006-07-01), Mrsny
patent: 2007/0003578 (2007-01-01), Fitzgerald
patent: 2007/0141070 (2007-06-01), Mrsny
patent: 2007/0148131 (2007-06-01), Mrsny
patent: 0439954 (1991-08-01), None
patent: WO90/13563 (1990-11-01), None
patent: WO93/11791 (1993-06-01), None
patent: WO95/31483 (1995-11-01), None
patent: WO97/13529 (1997-04-01), None
patent: WO98/20135 (1998-05-01), None
patent: WO99/02712 (1999-01-01), None
patent: WO99/57142 (1999-11-01), None
Sastry et al. (FEBS Letters, vol. 151, No. 2, 1983).
sequence alignment AC PO2973;Q53390.
Sastry et al. FEBS Letters, vol. 151, No. 2, 1983.
sequence alignment AC PO2973;Q53390. Nov. 1990.
U.S. Appl. No. 09/462,682, filed Apr. 28, 2000, Fitzgerald et al.
U.S. Appl. No. 10/110,880, filed Apr. 16, 2002, Fitzgerald et al.
Ashorn, P. et al., “Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors” PNAS USA 87:8889-8893 (1990).
Benhar, I. et al., “Pseudomonas Exotoxin A Mutants: Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner” J. Biol. Chem. 269(18):13398-13404 (1994).
Berger, E. et al., “CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses” PNAS USA 86:9539-9543 (1989).
Brinkmann, U. et al., “Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice” PNAS USA 89:3065-3069 (1992).
Brinkmann, U. et al., “Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: Influence of interdomain connections” PNAS USA 89:3075-3079 (1992).
Brinkmann, U. et al., “Immunotoxins against cancer” Biochimica et Biophysica Acta 1198:27-45 (1994).
Chaudhary, V. et al., “Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein” Nature 335:369-372 (1988).
Chaudhary, V. et al., “Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity” PNAS USA 87:308-312 (1990).
Chandhary, V. et al., “Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity” J. Biol. Chem. 265(27):16303-16310 (1990).
Choe, M. et al., “B3(Fab)-PE38M: A recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3” Cancer Res. 54:3460-3467 (1994).
Cryz, Jr., S. et al., “Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans” J. Clin. Invest. 80:51-56 (1987).
Cryz, Jr., S. et al., “Safety and immunogenicity ofEscherichia coliO18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans” J. Infect. Dis. 163:1040-1045 (1991).
Cryz, Jr., S. et al., “Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine” Vaccine 13(1):67-71 (1995).
Fattom, A. et al., “Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-Succinimidyl-3-(2-pridyldithio)propionate” Infection and Immunity 60(2):584-589 (1992).
Fattom, A. et al., “Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A” Infection and Immunity 61(3):1023-1032 (1993).
Fitzgerald, D.J. et al., “Characterization of V3 loop-Pseudonomas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1.” J. Biol. Chem., vol. 273, No. 16; pp. 9951-9958 (1998).
Hahn, H. et al., “Pilin-Based Anti-Pseudomonas Vaccines: Latest Developments and Perspectives” Behring Institute: Mitteilungen, Marburg, DE 98:315-325 (1997).
Hertle, R. et al., “Dual-Function Vaccine for Pseudomonas Aeruginosa: Characterization of Chimeric Exotoxin A-Pilin Protein” Infection and Immunity 69(11):6962-6969 (2001).
Jinno, Y. et al., “Domain II mutants of Pseudomonas exotoxin deficient in translocation” J. Biol. Chem. 264(27):15953-15959 (1989).
Johnson, K. et al., “Nucleotide sequence and transcriptional initiation site of two Pseudomonas aeruginosa pilin genes” J. Biol. Chem. 261(33):15703-15708 (1986).
Kasturi, S. et al., “Alanine scanning mutagenesis identifies surface amino acids on domain III of Pseudomonas exotoxin required for cytotoxicity, proper folding, and secretion into periplasm” J. Biol. Chem. 267(32):23427-23433 (1992).
Kondo, T. et al., “Activity of immunotoxins constructed with modified Pseudomona exotoxin A lacking the cell recognition domain” J. Biol. Chem. 263(19):9470-9475 (1988).
Kreitman, R. et al., “Properties of chimeric toxins with two recognition domains: Interleukin 6 and transofrming growth factor α at different locations in Pseudomonas exotoxin” Biocon. Chem 3:63:68 (1992).
Kuan, C. et al., “Pseudomonas exotoxin A mutants: Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner” J. Biol. Chem. 269(10):7610-7616 (1994).
Kuan, C. et al., “Improved antitumor activity of a recombinant anti-Lewisγimmunotoxin not requiring proteolytic activation” PNAS USA 93:974-
Jones Day
Mondesi Robert B.
Shahnan-Shah Khatol
Trinity Biosystems, Inc.
LandOfFree
Methods and compositions for immunizing against Pseudomonas... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for immunizing against Pseudomonas..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for immunizing against Pseudomonas... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4087178